Trial Profile
Phase II Multicenter Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Chordoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms PalboSarc
- 22 Jan 2024 Planned End Date changed from 31 Dec 2023 to 30 Sep 2024.
- 22 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Sep 2024.
- 07 Jun 2022 Results (n=22) presented at the 58th Annual Meeting of the American Society of Clinical Oncology